Table 1. Clinical characteristics of study participants.

	ACTG A5321 Cohort (n = 96)	Toronto cohort (n = 18)
Age at sample time point, median (range), years	43 (23–74)	47 (30–61)
Sex—female	26%	0%
Pre-therapy plasma HIV-1 RNA, median (range), log10 copies/ml	40,847 (190–979,159)	10,610 (<40–911,164)
Pre-therapy CD4+ T-cell count, median (range), cells/mm3	288 (0–734)	330 (52–460)
Years on therapy at sample time point, median (range), years	7 (4–15)	6 (2–25)
CD4 count at sample time point, median (range), cells/mm3	705 (149–1413)	650 (300–1000)

As an aside, no significant differences were observed between individuals on PI versus non-PI regimens with respect to the magnitudes of T-cell responses to any HIV gene products in this ACTG cohort (unpaired t tests: Gag, p = 0.87; Pol, p = 0.14; Nef/Tat/Rev p = 0.77; Env, p = 0.34; Vif/Vpr/Vpu, p = 0.93).